A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death by unknown
RESEARCH Open Access
A population-based analysis of the risk of
drug interaction between clarithromycin and
statins for hospitalisation or death
Bita Mesgarpour1,2, Ghazaleh Gouya1, Harald Herkner3, Berthold Reichardt4 and Michael Wolzt1*
Abstract
Background: Clarithromycin, known as a potent inhibitor of the cytochrome P450 isoenzyme CYP3A, may increase
the plasma concentration of statins metabolized by this pathway; therefore, increase the risk of interaction with statins
in reference to pharmacokinetic studies. This study aimed to characterize whether the concomitant use of a statin with
clarithromycin is associated with serious outcomes among adult persons.
Methods: Health claims data of adult persons in the Regional Sickness Fund of Burgenland, Austria, who filled a
prescription for clarithromycin between July 1, 2009 and June 30, 2012 were reviewed retrospectively. We assumed
that the risk of hospitalisation increases acutely with the indication for taking an antibiotic, whereas statin use can be
considered a chronic exposure with a low constant effect on hospitalisation. When defining the population as persons
taking clarithromycin and the use of statins as the exposure we could achieve a comparable effect in both groups from
the acute condition on hospitalisation. Therefore, we defined exposed patients as those who had overlapping treatment
with a statin and unexposed controls as those who had filled a prescription for clarithromycin without concomitant statin
therapy. Outcome was defined as a composite of hospital admission or death within 30 days after starting clarithromycin.
We used generalised linear regression to model an association between outcome and exposure to statins.
Results: Among 28,484 prescriptions of clarithromycin, 2317 persons were co-exposed to statins. Co-administration of
CYP3A4 metabolized statins and clarithromycin was associated with a 2.11 fold increased risk of death or hospitalisation
(95 % confidence interval [CI]: 1.79–2.48). This effect was explained by age, evidence of cardiovascular disease, diabetes
mellitus and utilization of other antibiotics (multivariable adjusted risk ratio: 1.02, 95 % CI: 0.85–1.22). The sensitivity
analyses did not change the significance of effect.
Conclusions: The risk for hospitalisation or death in persons receiving clarithromycin increases with age and
cardiovascular disease but is not causally associated with statin-clarithromycine co-administration.
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Background
The potential of interaction between drugs that inhibit the
CYP3A4 metabolic pathway and 3A4 substrates is well
recognised [1–8]. However, the clinical relevance of this
interaction is poorly defined and co-prescription of these
medications is common in the clinical setting [9–12].
Macrolide antibiotics such as clarithromycin are known
as potent inhibitors of CYP3A4, thus introducing the
potential for a pharmacological interaction with CYP3A4-
metabolised statins (atorvastatin, simvastatin and lova-
statin). Concomitant use of macrolides with statins 3A4
substrate was detected from 1.6 to 6.3 % in the electronic
medical records databases [9, 11].
Studies showed that co-administration of clarithromycin
have significant effect on pharmacokinetic parameters of
simvastatin and atorvastatin, with an approximately ten-
fold or fourfold increase in drug exposure as measured by
the area of the drug concentration versus time curve, re-
spectively. It was also associated with approximately
seven- to eightfold and greater than fivefold increase in
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maximum plasma concentration of simvastatin and ator-
vastatin, respectively [13, 14]. Study on the spontaneous
adverse event reports, using the US Food and Drug Ad-
ministration Adverse Event Reporting System database
showed a six fold increase in the adverse event reporting
rate and ratio (AERR) of rhabdomyolysis in concomitant
use of simvastatin with CYP3A4 inhibitors compared to
simvastatin without CYP3A4 inhibitors (56 events in
14,575,000 prescriptions versus 62 events in 103,822,000
prescriptions) [15]. Although, several case reports support
this interaction [16–23]. However, limited evidence from
controlled studies confirms and measures the potential risk
of serious adverse events due to this interaction [9, 24, 25].
Furthermore, none of them has the appropriate power to
recognize a specific CYP3A4 inhibitor-statins interaction.
In an effort to address the clinical impact of this drug-drug
interaction, we did a cohort study to investigate the risk of
hospitalization or death associated with co-prescription of a
statin with clarithromycin.
Results
In total, 69,877 HMG CoA reductase inhibitors were
prescribed in clarithromycin users (independent of co-
administration) during the observation period (Fig. 1). A
total of 28,484 prescriptions in 23,339 persons were
included in the analyses. We determined 2317 co-
administrations of statins and clarithromycin as exposed
Fig. 1 Clarithromycin and antilipidemic agents’ utilization in BGKK from 2009.07.01 to 2012.06.30
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persons comparing to 26,167 prescriptions of clarithro-
mycin only as unexposed control.
Person demographics and prescriptions are pre-
sented in Table 1. Among the persons who received
co-administrations of statins and clarithromycin, 206
(8.89 %) hospitalizations or deaths were observed dur-
ing the follow-up period. In the unexposed clarithro-
mycin group, 1128 (4.31 %) persons were hospitalized
or died during the observation period.
In the crude unadjusted analysis, current concomitant
use of CYP3A4 metabolized statins with clarithromycin
was associated with 2.11 (95 % CI: 1.79–2.48) times
higher risk for hospitalization or death compared to
clarithromycin without current concomitant use of
CYP3A4 metabolized statins (Table 2). Current age,
treatment with other antibiotics, evidence of diabetes
or cardiovascular disease each explained partly the ef-
fect of current statins on death or hospitalization in the
bivariate analyses. In multivariate combination, however,
these four variables fully account for the association be-
tween current statin use and the outcome of death or
hospitalization (multivariable adjusted RR: 1.02 (0.85–1.22).
The effects were virtually unchanged for persons younger
or older than 65 years (p-value for interaction 0.11). There
were also no other significant interactions on the effect of
current statin use on the outcome.
We conducted a sensitivity analyses to explore the im-
pact of frequency of clarithromycin use, hospital admission
or death within 5 or 10 days and death or hospitalisation
separately. Interaction of CYP3A4 metabolized statins and
clarithromycin was not significantly different with restric-
tion of exposed persons to those with first time prescrip-
tion of clarithromycin (RR = 0.96, 95 % CI: 0.79–1.16) or
on a one-time basis (RR = 0.92, 95 % CI: 0.74–1.13). Results
of the sensitivity analyses for death or hospitalization
within 5 or 10 days (RR = 0.78, 95 % CI: 0.55–1.12;
RR = 1.38, 95 % CI: 0.95–2.00), only hospitalisation or
only death within 30 days (RR = 1.01, 95 % CI: 0.84–1.21;
RR = 1.2, 95 % CI: 0.46–3.18) did not differ significantly
from our predefined outcome, death or hospitalisation
within 30 days.
Discussion
This population-based analysis of reimbursement data
suggest that hospital admission and mortality are similar
when clarithromycin is prescribed in the presence or ab-
sence of CYP3A4 substrate statins. This finding puts the
pharmacokinetic drug interaction into clinical perspective.
Our study suggests a lack of a causal effect for current
statin use on death or hospitalisation of clarithromycin
users. Increased clinical risk is driven by the effects of
age, evidence of diabetes or cardiovascular disease and
treatment with other antibiotics.
Table 1 Patient demographics and prescriptions
Exposed patients Unexposed controls
Age, mean ± SD 66.3 ± 11.1 46.8 ± 17.2










Current statin users 1959 –
History of disease n (%)a
Diabetes 622 (26.8 %) 1236 (4.7 %)
Cardiovascular disease 1906 (82.3 %) 7704 (29.4 %)
Malignancy 52 (2.2 %) 337 (1.3 %)
Autoimmune disorders 27 (1.2 %) 172 (0.7 %)
Antiplatelet drugs 665 (28.7 %) 860 (3.3 %)
P2Y12 inhibitors 194 (8.4 %) 136 (0.5 %)
ASA ± dipyridamole 537 (23.2 %) 757 (2.9 %)
Highly active antiretroviral
therapy
0 (0 %) 2 (0 %)
Concomitant medications
Other antilipidemic agents 116 (5.0 %) 241 (0.9 %)




Strong interaction 78 (3.4 %) 312 (1.2 %)
Moderate interaction 882 (38.1 %) 2859 (10.9 %)
Weak interaction 581 (25.1 %) 2768 (10.6 %)
Statins
Strong interaction 22 (0.9 %) –
Moderate interaction 4 (0.2 %) –
Weak interaction 21 (0.9 %) –
Drug-drug interaction
(antagonistic effect)b
Clarithromycin 2 (0.1 %) 8 (0.0 %)
Statins 0 (0.0 %) –
Outcomes
No. of hospitalization 198 (8.5 %) 1108 (4.2 %)
No. of death 8 (0.3 %) 20 (0.1 %)
ASA acetylsalicylic acid, CYP3A4 cytochrome P450 3A4, SD standard deviation
aConcomitant disease as suggested by co-medication
bSee the details in supplementary methods
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Our findings are consistent with a population-based
cohort study on the UK Health Improvement Network
(THIN) database, which detected no difference in the
relative hazard of muscle toxicity, renal dysfunction or
hepatic dysfunction in patients prescribed a statin
CYP3A4 substrate versus a statin non-CYP3A4 sub-
strate in co-medication with another CYP3A4 inhibitor
[26]. Our present study extends these findings, since it
has focussed on a specific CYP3A4 inhibitor in a large
population. Further, we adjusted our data for all pos-
sible drug interactions of clarithromycin and statins
such as antiretroviral therapy since our data was not
limited to general physicians’ prescriptions. The num-
ber of prescriptions of some classes of drugs, e.g. anti-
retroviral treatments, was however too small to draw
meaningful conclusions and to rule out relevant clinical
effects. We also adjusted for prescription of other sys-
temic antibiotics during the observation period as
proxy for the severity of disease.
Likewise, a Canadian population-based, nested case-
control study has evaluated drug-drug interaction of
donepezil, which is metabolized by CYP3A4, and clari-
thromycin. The risk of adverse cardiovascular events
was not increased by concurrent administration of clari-
thromycin in elderly donepezil users compared with azi-
thromycin, which does not interact with the cytochrome
P-450 system (OR = 0.67; 95 % CI:0.28–1.63; p = 0.38)
[27]. In contrast, a recent Canadian population-based co-
hort study detected a higher risk for hospitalization with
rhabdomyolysis (RR = 2.17, 95 % CI:1.04–4.53), acute kid-
ney injury (RR = 1.78, 95 % CI, 1.49–2.14) and for all-
cause mortality (RR = 1.56, 95 % CI: 1.36–1.80) in older
people associated with co-prescription of a CYP3A4 me-
tabolized statin with clarithromycin or erythromycin
compared with azithromycin. [25] Another Canadian
population-based cohort study found that co-prescription
of clarithromycin versus azithromycin with a calcium-
channel blocker was associated with a higher risk of
hospitalization with acute kidney injury (OR = 1.98, 95 %
CI: 1.68–2.34) [28].
The result of our study is at variance with a study on
dispensed prescriptions of lipid-lowering drugs using ad-
ministrative claims data from diverse regions in the
United States. The increased risk of hospitalization due to
myopathy, renal and hepatic adverse medical events has
been identified in lipid-lowering drug users with co-
administration of CYP3A4 inhibitors (RR = 6.01, 95 % CI:
2.08–17.38; RR = 2.29, 95 % CI: 1.62–3.23; and RR = 2.55,
95 % CI: 1.76–3.70, respectively) [24]. Although, this study
has the limitation of a case-control study design, not con-
trolling of confounding variables like history of other dis-
ease, as well as lack of subgroup analysis for detecting the
effect of statins-CYP3A4 inhibitors interaction. Moreover,
monotherapy with statins are generally well tolerated
and present a safe profile. Therefore, the choice of ana-
lysis, comparing the co-administration of statins and
clarithromycin with monotherapy of statins or mono-
therapy of clarithromycin might affect the risk of ser-
ious adverse events of co-administration.
As we conducted a database analysis of prescription
data, medication adherence is not accounted for. In
addition, the possibility of a transient interruption of statin
intake during clarithromycin therapy by physician advice
was not accessible from our database. These factors would
have concealed a drug-drug interaction.
This study does not indicate an increased risk for hos-
pitalisations or death when clarithromycin is prescribed
with statins in a cohort of unselected persons in primary
care. The well-described pharmacokinetic interaction of
these medicines does not result in an increased precipi-
tation of serious clinical endpoints.
Methods
Population
We established a cohort of persons aged 18 years or older
in the Regional Sickness Fund of Burgenland (BGKK) who
filled a prescription for reimbursement of clarithromycin
between July 1, 2009 and June 30, 2012. The Austrian in-
surance system provides almost complete coverage of
health care for all residents. According to their current
employment or providence of residence, the membership
to the regional Burgenland Sickness Fund is assigned. We
received data from outpatient as well as inpatient medical
services covered by the health insurance fund, which were
stored in the respective anonymised dataset, including
demographic data, information on hospital admissions
and discharges with primary diagnoses coded using the
International Classification of Diseases (ICD) system and
drug prescriptions received. The data linkage with vital
status of persons was provided by Statistik Austria. There
was no ICD information of the extramural medical care
Table 2 Risk estimate in current concomitant use of CYP3A4
metabolized statins with clarithromycin within 30 days
Risk of death or hospitalisation RR (95 % CI) P value
Unadjusted risk 2.11 (1.79–2.48) <0.001
Adjusted for
Current agea 1.18 (1.00–1.40) 0.049
Diabetes mellitus 1.60 (1.34–1.91) <0.001
Cardiovascular disease 1.33 (1.12–1.57) 0.001




and other antibiotic therapy
1.02 (0.85–1.22) 0.85
Estimates come from a generalised linear model using a log link function;
confidence intervals are based on robust standard errors
acurrent age as indicator variable of quintiles
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included. The date of dispensing clarithromycin served as
the date of cohort entry (entry date). For persons who had
multiple prescription of clarithromycin, we classified treat-
ment as a new case if there was a gap of 3 months or more
between the end date of utilization of clarithromycin and
starting the new course. The initial unit of analysis was a
course of clarithromycin treatment (accounting for within-
person correlation). For a secondary analysis, we handled
single persons as the unit of analysis and used the first
course of clarithromycin, ignoring further courses of clari-
thromycin treatment.
For each person, we determined the total duration of
clarithromycin treatment using Defined Daily Dose (DDD)
information from WHO; this information was used as a
covariate in the analyses.
Exposed persons
We assumed that the risk of hospitalisation increases
acutely with the indication for taking an antibiotic, whereas
statin use can be considered a chronic exposure with a low
constant effect on hospitalisation. When defining the
population as persons taking clarithromycin and the use of
statins as the exposure we could achieve a comparable ef-
fect in both groups from the acute condition on hospital-
isation. Given that we were able to adjust for confounding
by indication for statin use we assume that this approach
enabled us to appropriately examine the drug-drug inter-
action of statins and clarithromycin. Given the absence of
detailed clinical information in the database, we were not
able to adjust for factors related to the indication of clari-
thromycin use, therefore an approach of comparing clari-
thromycin exposure in a population of statin users
appeared less promising. Therefore, we identified persons
who had a statin co-prescribed during clarithromycin treat-
ment. We defined exposed persons as those who were
treated with clarithromycin and had overlapping treatment
with a statin at least for 1 day (concomitant users). We de-
fined ‘current statin users’ if a person had utilized a statin
within 5 days before the entry date. Exposure status was
stratified by statins metabolized by the enzyme CYP3A4
(atorvastatin, lovastatin, pravastatin, simvastatin) and those
metabolized by the CYP2C9 (fluvastatin, rosuvastatin).
Unexposed persons
Persons that had no overlapping statin exposure dur-
ing their clarithromycin treatment were determined
as controls.
Outcome
Outcome was defined as a composite of hospital admis-
sion or death within 30 days. In separate sensitivity ana-
lyses, we assigned hospital admission as endpoint if it
happened within 5, 10 and 30 days after starting clari-
thromycin (entry date).
Observation time
We defined the exit date as the date of the occurrence
of the outcome or the end of the observation time. Ob-
servation time = exit date - entry date.
Covariates
Prescriptions of drugs used to treat diabetes (ATC code
A10), cardiovascular disease (ATC code B01, C01, C02,
C03, C04, C07, C08, C09), malignancy (ATC code: L01,
L02B, L03), autoimmune disorders (ATC code: L04) and
other antilipidemic (ATC code: C10AB, C10AC, C10AD,
C10AX and C10B) before the entry date used to identify
relevant disease in cases and controls. We identified
antiplatelet drugs including P2Y12 inhibitors (ATC code:
B01AC04, B01AC22, B01AC24), aspirin and combination
of aspirin and dipyridamole (ATC code: B01AC06,
B01AC30) as proxies for manifestation of cardiovascular
disease. Highly active antiretroviral therapy (HAART) used
to treat HIV infection has been detected based on recom-
mended guidelines [29, 30]. We defined the person’s his-
tory of the above disease if the relevant medications have
been prescribed at least 6 month before the cohort entry.
Clarithromycin is metabolized by the enzyme CYP3A4
(CYP3A4 substrate) and acts as an inhibitor of the metab-
olizing enzyme CYP3A4. Therefore, we defined the list of
agents inhibiting and inducing CYP3A metabolism as well
as other drugs with synergistic/antagonistic effects on
clarithromycin or statins to detect co-administration of
each one (as confounder of the effect of clarithromycin on
statins) during the observation period (Additional file 1).
We used prescription of other systemic antibiotics (ATC
code-J01) during the observation period as proxy for the
severity of disease. We compared the frequency of the
outcome between exposed persons and unexposed con-
trols. Baseline data, demographics and risk or exposure
related covariates were tabulated and compared using
two-sided hypothesis tests.
Statistical analyses
We used a generalised linear regression model to assess
the association between the outcome and the exposure to
statins with a log-link function to get directly risk ratios
(RR) as the measure of effect. For the main analysis, the
exposure was current concomitant use of CYP3A4 meta-
bolised statins and the outcome was death or hospitalisa-
tion within 30 days. The unit of analysis for these models
was a course of clarithromycin treatment. We allowed for
within person correlation in case of repeated treatment
courses by using robust standard errors. To adjust for po-
tential confounding, we also included candidate covariates
if they changed the main effect by >10 % in a bivariate
analysis and if they were not considered moderator vari-
ables. We tested for first order interactions by including
interaction terms into the models. We performed several
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sensitivity analyses to assess the robustness of our esti-
mates. Accordingly, we repeated our analyses using several
definitions of exposure status by exposure time and statin
type. We also analysed hospitalisation and mortality separ-
ately. Likewise, the analyses have been repeated by allow-
ing for varying the outcome time definitions. We also
used several modelling approaches (including logistic re-
gression and proportional hazards regression) and
methods for handling correlated data (robust standard er-
rors or random effects models).
Data analysis was performed using Microsoft Excel and
Stata 11 (Stata Corp, College Station, TX). A two-sided p-
value <0.05 was considered statistically significant.
Additional file
Additional file 1: Drug Interactions for clarithromycin and statins.
Synergistic Interactions with Clarithromycin. Major Inducers of CYP3A4.
Synergistic Interactions with Simvastatin, Lovastatin, Pravastatin,
Fluvastatin, Atorvastatin, Rosuvastatin. Antagonistic Interaction with
Simvastatin, Lovastatin, Pravastatin, Fluvastatin, Atorvastatin. (PDF 470 kb)
Abbreviation
AERR: Adverse event reporting rate and ratio; BGKK: Regional Sickness Fund
of Burgenland; DDD: Defined Daily Dose; ICD: International Classification of
Diseases; THIN: The UK Health Improvement Network.
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